Feasibility of the Multiple Sclerosis Performance Test in Participants With Multiple Sclerosis
NCT03926637 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 3073
Last updated 2023-01-30
Summary
The primary objective is to evaluate the feasibility of the Multiple Sclerosis Performance Test (MSPT) in a clinical care setting when used by participants with Multiple Sclerosis (MS).
Conditions
Interventions
- OTHER
-
Multiple Sclerosis Performance Test (MSPT)
Administered as specified in the treatment arm.
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Medical Director · Biogen
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-06-17
- Primary Completion
- 2022-12-05
- Completion
- 2022-12-05
Countries
- United States
- Czechia
- France
- Italy
- Switzerland
- United Kingdom
Study Locations
More Related Trials
-
Effect of Alemtuzumab on Microglial Activation Positron Emission Tomography (PET) in Multiple Sclerosis
NCT03983252 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
The Use of Technology to Improve MS Clinical Trials and Patient Care
NCT02454907 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Physical and Cognitive Performance During the Two First Years of Lemtrada Treatment
NCT03806387 ·Status: COMPLETED
-
A Single-blinded, Controlled, Multi-centre Study of Effects of Exercise in Participants With Multiple Sclerosis
NCT01065090 ·Status: COMPLETED
-
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
NCT02936037 ·Status: TERMINATED ·Phase: PHASE3
-
A Study for Patients With Multiple Sclerosis
NCT00870155 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
A Study for Patients With Secondary Progressive Multiple Sclerosis
NCT00869726 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Progression of Cognitive and Physical Symptoms in Multiple Sclerosis
NCT00922831 ·Status: WITHDRAWN
-
An Observational Biomarker Study in Multiple Sclerosis (MS) Patients
NCT05663853 ·Status: COMPLETED
-
ATX-MS-1467 in Multiple Sclerosis
NCT01973491 ·Status: COMPLETED ·Phase: PHASE2
-
Feasibility and Reliability of Multimodal Evoked Potentials
NCT03686826 ·Status: COMPLETED
-
The Effect of Rituximab on Cognitive and Hand Functions in Secondary Progressive Multiple Sclerosis
NCT06599307 ·Status: RECRUITING ·Phase: PHASE2
-
PREG-MS: New England MS Pregnancy Registry
NCT03368157 ·Status: COMPLETED
-
Efficacy and Safety of BG00012 in MS
NCT00168701 ·Status: COMPLETED ·Phase: PHASE2
-
A "negative"dendritic Cell-based Vaccine for the Treatment of Multiple Sclerosis: a First-in-human Clinical Trial
NCT02618902 ·Status: COMPLETED ·Phase: PHASE1
-
COVID-19 Vaccine Response in Treated MS Patients
NCT05060354 ·Status: COMPLETED
-
MitoQ for Fatigue in Multiple Sclerosis
NCT03166800 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Evaluating Multiple Sclerosis Patients ShOWing A GEnomic Signature of Therapy Response
NCT03316404 ·Status: COMPLETED
-
RIPC on Activity, Fatigue and Gait in MS
NCT03967106 ·Status: COMPLETED ·Phase: NA
-
MultiSCRIPT-Cycle 1: Personalized Medicine in Multiple Sclerosis - Pragmatic Platform Trial Embedded Within the SMSC
NCT06095271 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Study of NG01 Cell Therapy in Secondary Progressive Multiple Sclerosis
NCT06961383 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Allogenic Adipose Tissue-derived Mesenchymal Stromal Cells for the Treatment of Primary Progressive Multiple Sclerosis
NCT06592703 ·Status: RECRUITING ·Phase: PHASE1
-
People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists
NCT07207148 ·Status: RECRUITING
-
Serum Neurofilament Light in Multiple Sclerosis
NCT06282081 ·Status: ACTIVE_NOT_RECRUITING
-
Remote Evaluation in Patients With Multiple Sclerosis
NCT06308042 ·Status: NOT_YET_RECRUITING